



Cite this: *Chem. Commun.*, 2015, 51, 17775

DOI: 10.1039/c5cc90543e

www.rsc.org/chemcomm

Correction: Acid-labile boronate-bridged dextran–bortezomib conjugate with up-regulated hypoxic tumor suppression

Weiguo Xu, Jianxun Ding,* Lingyu Li, Chunsheng Xiao, Xiuli Zhuang and Xuesi Chen

Correction for 'Acid-labile boronate-bridged dextran–bortezomib conjugate with up-regulated hypoxic tumor suppression' by Weiguo Xu *et al.*, *Chem. Commun.*, 2015, **51**, 6812–6815.

The annotation in Fig. 3A was incorrect, and the unit of the half-maximal inhibitory concentration (IC_{50}) in Fig. 3B was wrong. The correct version of Fig. 3 is shown below.




Fig. 3 *In vitro* cytotoxicities (A) and IC_{50} s (B) of Dex–BTZ and BTZ after incubation for 48 h toward HepG2 cells. The data were presented as mean \pm standard deviation ($n = 3$, * $p < 0.05$, # $p < 0.001$).

In addition, the unit for the IC_{50} values stated in lines 5 and 7 of the right column of page 3 is incorrectly displayed as “nM”. The correct unit is “ μM ”.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

